Evidence map›Paper›PMID 27703158›Full record

ArticleThe Journal of antibiotics2017

Three structurally-related impurities in norvancomycin drug substance.

Zhibo Jiang, Xuan Lei, Minghua Chen, Bingya Jiang, Linzhuan Wu, Xuexia Zhang, Zhihui Zheng, Xinxin Hu, Xuefu You, Shuyi Si and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Looking Back toAntibiotics (Basel, Switzerland) · 2021
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhibo JiangKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xuan LeiKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Minghua ChenKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bingya JiangKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Linzhuan WuKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xuexia ZhangNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, Hebei China.
Zhihui ZhengNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, Hebei China.
Xinxin HuKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xuefu YouKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuyi SiKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lifei WangKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bin HongKey Laboratory of Biotechnology of Antibiotics, the National Health and Family Planning Commission (NHFPC); Department of Biotechnology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norvancomycin (NVCM) is widely used in China to treat bacterial infections of Gram-positive cocci and bacilli, especially infections of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis. This study is a chemical investigation of the drug substance of NVCM, and led to the identification, by 1D, 2D NMR spectra and HRESIMS, of three as yet undescribed impurities, one D-O-E ring expanded NVCM analog (1) and two derivatives of NVCM lacking sugars (2, 3).

Indexed as

Anti-Bacterial AgentsDrug ContaminationMolecular StructureVancomycinAnti-Bacterial AgentsnorvancomycinVancomycin

Identifiers

PMID27703158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.